UK NICE Processes Not Fit For Orphan Drugs, Says New Report
Executive Summary
UK health technology appraisal body NICE says it will carefully review a new report that has found its processes block access to orphan drugs.
You may also be interested in...
Real-World Data Boost Santhera's Latest DMD Filing, And The Markets Agree
Despite being knocked back twice, Santhera CEO Thomas Meier is still confident Raxone has a place as a Duchenne muscular dystrophy therapy, and believes new long-term data will strengthen its third application to the EU in the coming months.
New UK Price Deal To Save NHS £930m & Speed Up Access To Innovation
The revised PPRS, which is expected to take effect at the beginning of 2019, will implement a 2% cap on the growth in sales of branded medicines to the NHS that should result in substantial savings on medicines spending. It also provides for faster NICE appraisals for non-cancer drugs, and more flexibility in commercial discussions between companies and the health department.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.